-
1
-
-
80052852254
-
-
World Health Organization. Immunization coverage
-
World Health Organization. Immunization coverage. World Health Organization http://www. who. int/ mediacentre/factsheets/fs378/en (2017).
-
(2017)
World Health Organization
-
-
-
2
-
-
84991822099
-
Childhood vaccination: Implications for global and domestic public health
-
Younger, D. S., Younger, A. P. & Guttmacher, S. Childhood vaccination: implications for global and domestic public health. Neurol. Clin. 34, 1035-1047 (2016).
-
(2016)
Neurol. Clin.
, vol.34
, pp. 1035-1047
-
-
Younger, D.S.1
Younger, A.P.2
Guttmacher, S.3
-
3
-
-
73449088379
-
Vaccines: The fourth century
-
Plotkin, S. A. Vaccines: the fourth century. Clin. Vaccine Immunol. 16, 1709-1719 (2009).
-
(2009)
Clin. Vaccine Immunol.
, vol.16
, pp. 1709-1719
-
-
Plotkin, S.A.1
-
4
-
-
85026212979
-
Whither vaccines
-
Rodrigues, C. M. C., Pinto, M. V., Sadarangani, M. & Plotkin, S. A. Whither vaccines J. Infect. 74 (Suppl. 1), S2-S9 (2017).
-
(2017)
J. Infect.
, vol.74
, pp. S2-S9
-
-
Rodrigues, C.M.C.1
Pinto, M.V.2
Sadarangani, M.3
Plotkin, S.A.4
-
5
-
-
0025231388
-
Direct gene transfer into mouse muscle in vivo
-
Wolff, J. A. et al. Direct gene transfer into mouse muscle in vivo. Science 247, 1465-1468 (1990).
-
(1990)
Science
, vol.247
, pp. 1465-1468
-
-
Wolff, J.A.1
-
6
-
-
0026522713
-
Reversal of diabetes insipidus in Brattleboro rats: Intrahypothalamic injection of vasopressin mRNA
-
Jirikowski, G. F., Sanna, P. P., Maciejewski-Lenoir, D. & Bloom, F. E. Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA. Science 255, 996-998 (1992).
-
(1992)
Science
, vol.255
, pp. 996-998
-
-
Jirikowski, G.F.1
Sanna, P.P.2
Maciejewski-Lenoir, D.3
Bloom, F.E.4
-
7
-
-
85038845677
-
Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity
-
Suschak, J. J., Williams, J. A. & Schmaljohn, C. S. Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity. Hum. Vaccin. Immunother. 13, 2837-2848 (2017).
-
(2017)
Hum. Vaccin. Immunother.
, vol.13
, pp. 2837-2848
-
-
Suschak, J.J.1
Williams, J.A.2
Schmaljohn, C.S.3
-
8
-
-
84961156254
-
Liposome-based adjuvants for subunit vaccines: Formulation strategies for subunit antigens and immunostimulators
-
Tandrup Schmidt, S., Foged, C., Korsholm, K. S., Rades, T. & Christensen, D. Liposome-based adjuvants for subunit vaccines: formulation strategies for subunit antigens and immunostimulators. Pharmaceutics 8, E7 (2016).
-
(2016)
Pharmaceutics
, vol.8
, pp. E7
-
-
Tandrup Schmidt, S.1
Foged, C.2
Korsholm, K.S.3
Rades, T.4
Christensen, D.5
-
9
-
-
54949112814
-
Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability
-
Kariko, K. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16, 1833-1840 (2008).
-
(2008)
Mol. Ther.
, vol.16
, pp. 1833-1840
-
-
Kariko, K.1
-
10
-
-
84954288084
-
Materials for non-viral intracellular delivery of messenger RNA therapeutics
-
Kauffman, K. J., Webber, M. J. & Anderson, D. G. Materials for non-viral intracellular delivery of messenger RNA therapeutics. J. Control. Release 240, 227-234 (2016).
-
(2016)
J. Control. Release
, vol.240
, pp. 227-234
-
-
Kauffman, K.J.1
Webber, M.J.2
Anderson, D.G.3
-
11
-
-
85011596037
-
Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems
-
Guan, S. & Rosenecker, J. Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems. Gene Ther. 24, 133-143 (2017).
-
(2017)
Gene Ther.
, vol.24
, pp. 133-143
-
-
Guan, S.1
Rosenecker, J.2
-
12
-
-
84940720241
-
Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals
-
Thess, A. et al. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol. Ther. 23, 1456-1464 (2015).
-
(2015)
Mol. Ther.
, vol.23
, pp. 1456-1464
-
-
Thess, A.1
-
13
-
-
82255194361
-
Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA
-
Kariko, K., Muramatsu, H., Ludwig, J. & Weissman, D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 39, e142 (2011).
-
(2011)
Nucleic Acids Res.
, vol.39
, pp. e142
-
-
Kariko, K.1
Muramatsu, H.2
Ludwig, J.3
Weissman, D.4
-
14
-
-
84921353914
-
mRNA transcript therapy
-
Weissman, D. mRNA transcript therapy. Expert Rev. Vaccines 14, 265-281 (2015).
-
(2015)
Expert Rev. Vaccines
, vol.14
, pp. 265-281
-
-
Weissman, D.1
-
15
-
-
84921794613
-
mRNA-based therapeutics - Developing a new class of drugs
-
Sahin, U., Kariko, K. & Tureci, O. mRNA-based therapeutics - developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759-780 (2014).
-
(2014)
Nat. Rev. Drug Discov.
, vol.13
, pp. 759-780
-
-
Sahin, U.1
Kariko, K.2
Tureci, O.3
-
16
-
-
84878664092
-
In vitro transcription of long RNA containing modified nucleosides
-
Pardi, N., Muramatsu, H., Weissman, D. & Kariko, K. In vitro transcription of long RNA containing modified nucleosides. Methods Mol. Biol. 969, 29-42 (2013).
-
(2013)
Methods Mol. Biol.
, vol.969
, pp. 29-42
-
-
Pardi, N.1
Muramatsu, H.2
Weissman, D.3
Kariko, K.4
-
17
-
-
0036794062
-
Stability of endogenous and added RNA in blood specimens, serum, and plasma
-
Tsui, N. B., Ng, E. K. & Lo, Y. M. Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin. Chem. 48, 1647-1653 (2002).
-
(2002)
Clin. Chem.
, vol.48
, pp. 1647-1653
-
-
Tsui, N.B.1
Ng, E.K.2
Lo, Y.M.3
-
18
-
-
84870869040
-
Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection
-
Petsch, B. et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat. Biotechnol. 30, 1210-1216 (2012).
-
(2012)
Nat. Biotechnol.
, vol.30
, pp. 1210-1216
-
-
Petsch, B.1
-
19
-
-
84865994357
-
Nonviral delivery of self-amplifying RNA vaccines
-
Geall, A. J. et al. Nonviral delivery of self-amplifying RNA vaccines. Proc. Natl Acad. Sci. USA 109, 14604-14609 (2012).
-
(2012)
Proc. Natl Acad. Sci. USA
, vol.109
, pp. 14604-14609
-
-
Geall, A.J.1
-
20
-
-
85015230578
-
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination
-
Pardi, N. et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543, 248-251 (2017).
-
(2017)
Nature
, vol.543
, pp. 248-251
-
-
Pardi, N.1
-
21
-
-
84945466813
-
Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes
-
Pardi, N. et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J. Control. Release 217, 345-351 (2015).
-
(2015)
J. Control. Release
, vol.217
, pp. 345-351
-
-
Pardi, N.1
-
22
-
-
85018162127
-
Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses
-
Bahl, K. et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol. Ther. 25, 1316-1327 (2017).
-
(2017)
Mol. Ther.
, vol.25
, pp. 1316-1327
-
-
Bahl, K.1
-
23
-
-
0022219780
-
Half-lives of beta and gamma globin messenger RNAs and of protein synthetic capacity in cultured human reticulocytes
-
Ross, J. & Sullivan, T. D. Half-lives of beta and gamma globin messenger RNAs and of protein synthetic capacity in cultured human reticulocytes. Blood 66, 1149-1154 (1985).
-
(1985)
Blood
, vol.66
, pp. 1149-1154
-
-
Ross, J.1
Sullivan, T.D.2
-
24
-
-
33845497677
-
Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells
-
Holtkamp, S. et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 108, 4009-4017 (2006).
-
(2006)
Blood
, vol.108
, pp. 4009-4017
-
-
Holtkamp, S.1
-
25
-
-
0026038913
-
The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency
-
Gallie, D. R. The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency. Genes Dev. 5, 2108-2116 (1991).
-
(1991)
Genes Dev.
, vol.5
, pp. 2108-2116
-
-
Gallie, D.R.1
-
26
-
-
0016709353
-
Purification of mRNA guanylyltransferase and mRNA (guanine-7-) methyltransferase from vaccinia virions
-
Martin, S. A., Paoletti, E. & Moss, B. Purification of mRNA guanylyltransferase and mRNA (guanine-7-) methyltransferase from vaccinia virions. J. Biol. Chem. 250, 9322-9329 (1975).
-
(1975)
J. Biol. Chem.
, vol.250
, pp. 9322-9329
-
-
Martin, S.A.1
Paoletti, E.2
Moss, B.3
-
27
-
-
0034768443
-
Synthesis and properties of mRNAs containing the novel "anti-reverse" cap analogs 7-methyl(3β-O-methyl)GpppG and 7-methyl (3β-deoxy)GpppG
-
Stepinski, J., Waddell, C., Stolarski, R., Darzynkiewicz, E. & Rhoads, R. E. Synthesis and properties of mRNAs containing the novel "anti-reverse" cap analogs 7-methyl(3β-O-methyl)GpppG and 7-methyl (3β-deoxy)GpppG. RNA 7, 1486-1495 (2001).
-
(2001)
RNA
, vol.7
, pp. 1486-1495
-
-
Stepinski, J.1
Waddell, C.2
Stolarski, R.3
Darzynkiewicz, E.4
Rhoads, R.E.5
-
28
-
-
3142714019
-
Cationic liposome-mediated RNA transfection
-
Malone, R. W., Felgner, P. L. & Verma, I. M. Cationic liposome-mediated RNA transfection. Proc. Natl Acad. Sci. USA 86, 6077-6081 (1989).
-
(1989)
Proc. Natl Acad. Sci. USA
, vol.86
, pp. 6077-6081
-
-
Malone, R.W.1
Felgner, P.L.2
Verma, I.M.3
-
29
-
-
3042782585
-
Codon bias and heterologous protein expression
-
Gustafsson, C., Govindarajan, S. & Minshull, J. Codon bias and heterologous protein expression. Trends Biotechnol. 22, 346-353 (2004).
-
(2004)
Trends Biotechnol.
, vol.22
, pp. 346-353
-
-
Gustafsson, C.1
Govindarajan, S.2
Minshull, J.3
-
30
-
-
84908701702
-
A critical analysis of codon optimization in human therapeutics
-
Mauro, V. P. & Chappell, S. A. A critical analysis of codon optimization in human therapeutics. Trends Mol. Med. 20, 604-613 (2014).
-
(2014)
Trends Mol. Med.
, vol.20
, pp. 604-613
-
-
Mauro, V.P.1
Chappell, S.A.2
-
31
-
-
33745198703
-
High guanine and cytosine content increases mRNA levels in mammalian cells
-
Kudla, G., Lipinski, L., Caffin, F., Helwak, A. & Zylicz, M. High guanine and cytosine content increases mRNA levels in mammalian cells. PLoS Biol. 4, e180 (2006).
-
(2006)
PLoS Biol.
, vol.4
, pp. e180
-
-
Kudla, G.1
Lipinski, L.2
Caffin, F.3
Helwak, A.4
Zylicz, M.5
-
32
-
-
64849114915
-
Coding-sequence determinants of gene expression in Escherichia coli
-
Kudla, G., Murray, A. W., Tollervey, D. & Plotkin, J. B. Coding-sequence determinants of gene expression in Escherichia coli. Science 324, 255-258 (2009).
-
(2009)
Science
, vol.324
, pp. 255-258
-
-
Kudla, G.1
Murray, A.W.2
Tollervey, D.3
Plotkin, J.B.4
-
33
-
-
84957689489
-
Synonymous codons direct cotranslational folding toward different protein conformations
-
Buhr, F. et al. Synonymous codons direct cotranslational folding toward different protein conformations. Mol. Cell 61, 341-351 (2016).
-
(2016)
Mol. Cell
, vol.61
, pp. 341-351
-
-
Buhr, F.1
-
34
-
-
84940891331
-
Codon usage influences the local rate of translation elongation to regulate co-translational protein folding
-
Yu, C. H. et al. Codon usage influences the local rate of translation elongation to regulate co-translational protein folding. Mol. Cell 59, 744-754 (2015).
-
(2015)
Mol. Cell
, vol.59
, pp. 744-754
-
-
Yu, C.H.1
-
35
-
-
85017425228
-
RNA sensors of the innate immune system and their detection of pathogens
-
Chen, N. et al. RNA sensors of the innate immune system and their detection of pathogens. IUBMB Life 69, 297-304 (2017).
-
(2017)
IUBMB Life
, vol.69
, pp. 297-304
-
-
Chen, N.1
-
36
-
-
78650640612
-
Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity
-
Fotin-Mleczek, M. et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J. Immunother. 34, 1-15 (2011).
-
(2011)
J. Immunother.
, vol.34
, pp. 1-15
-
-
Fotin-Mleczek, M.1
-
37
-
-
77953931139
-
Particle size and activation threshold: A new dimension of danger signaling
-
Rettig, L. et al. Particle size and activation threshold: a new dimension of danger signaling. Blood 115, 4533-4541 (2010).
-
(2010)
Blood
, vol.115
, pp. 4533-4541
-
-
Rettig, L.1
-
38
-
-
0030267336
-
The eIF-2 kinases and the control of protein synthesis
-
de Haro, C., Mendez, R. & Santoyo, J. The eIF-2 kinases and the control of protein synthesis. FASEB J. 10, 1378-1387 (1996).
-
(1996)
FASEB J.
, vol.10
, pp. 1378-1387
-
-
De Haro, C.1
Mendez, R.2
Santoyo, J.3
-
39
-
-
33749150990
-
RNase L: Its biological roles and regulation
-
Liang, S. L., Quirk, D. & Zhou, A. RNase L: its biological roles and regulation. IUBMB Life 58, 508-514 (2006).
-
(2006)
IUBMB Life
, vol.58
, pp. 508-514
-
-
Liang, S.L.1
Quirk, D.2
Zhou, A.3
-
40
-
-
84994908842
-
Structural analysis reveals that Toll-like receptor 7 is a dual receptor for guanosine and single-stranded RNA
-
Zhang, Z. et al. Structural analysis reveals that Toll-like receptor 7 is a dual receptor for guanosine and single-stranded RNA. Immunity 45, 737-748 (2016).
-
(2016)
Immunity
, vol.45
, pp. 737-748
-
-
Zhang, Z.1
-
41
-
-
84926395729
-
Toll-like receptor 8 senses degradation products of single-stranded RNA
-
Tanji, H. et al. Toll-like receptor 8 senses degradation products of single-stranded RNA. Nat. Struct. Mol. Biol. 22, 109-115 (2015).
-
(2015)
Nat. Struct. Mol. Biol.
, vol.22
, pp. 109-115
-
-
Tanji, H.1
-
42
-
-
0343185886
-
Foreign nucleic acids as the stimulus to make interferon
-
Isaacs, A., Cox, R. A. & Rotem, Z. Foreign nucleic acids as the stimulus to make interferon. Lancet 2, 113-116 (1963).
-
(1963)
Lancet
, vol.2
, pp. 113-116
-
-
Isaacs, A.1
Cox, R.A.2
Rotem, Z.3
-
43
-
-
84907527348
-
Transcriptome-wide mapping reveals widespread dynamic-regulated pseudouridylation of ncRNA and mRNA
-
Schwartz, S. et al. Transcriptome-wide mapping reveals widespread dynamic-regulated pseudouridylation of ncRNA and mRNA. Cell 159, 148-162 (2014).
-
(2014)
Cell
, vol.159
, pp. 148-162
-
-
Schwartz, S.1
-
44
-
-
84922180958
-
Pseudouridine profiling reveals regulated mRNA pseudouridylation in yeast and human cells
-
Carlile, T. M. et al. Pseudouridine profiling reveals regulated mRNA pseudouridylation in yeast and human cells. Nature 515, 143-146 (2014).
-
(2014)
Nature
, vol.515
, pp. 143-146
-
-
Carlile, T.M.1
-
45
-
-
84945455309
-
N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice
-
Andries, O. et al. N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J. Control. Release 217, 337-344 (2015).
-
(2015)
J. Control. Release
, vol.217
, pp. 337-344
-
-
Andries, O.1
-
46
-
-
77957242130
-
Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation
-
Anderson, B. R. et al. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res. 38, 5884-5892 (2010).
-
(2010)
Nucleic Acids Res.
, vol.38
, pp. 5884-5892
-
-
Anderson, B.R.1
-
47
-
-
82255164455
-
Nucleoside modifications in RNA limit activation of 2β-5β-oligoadenylate synthetase and increase resistance to cleavage by RNase L
-
Anderson, B. R. et al. Nucleoside modifications in RNA limit activation of 2β-5β-oligoadenylate synthetase and increase resistance to cleavage by RNase L. Nucleic Acids Res. 39, 9329-9338 (2011).
-
(2011)
Nucleic Acids Res.
, vol.39
, pp. 9329-9338
-
-
Anderson, B.R.1
-
48
-
-
23844464444
-
Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA
-
Kariko, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165-175 (2005).
-
(2005)
Immunity
, vol.23
, pp. 165-175
-
-
Kariko, K.1
Buckstein, M.2
Ni, H.3
Weissman, D.4
-
49
-
-
84988663801
-
Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles in vivo
-
Kauffman, K. J. et al. Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles in vivo. Biomaterials 109, 78-87 (2016).
-
(2016)
Biomaterials
, vol.109
, pp. 78-87
-
-
Kauffman, K.J.1
-
50
-
-
84927176976
-
A cationic nanoemulsion for the delivery of next-generation RNA vaccines
-
Brito, L. A. et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol. Ther. 22, 2118-2129 (2014).
-
(2014)
Mol. Ther.
, vol.22
, pp. 2118-2129
-
-
Brito, L.A.1
-
51
-
-
84921370516
-
The ReNAissanCe of mRNA-based cancer therapy
-
Van Lint, S. et al. The ReNAissanCe of mRNA-based cancer therapy. Expert Rev. Vaccines 14, 235-251 (2015).
-
(2015)
Expert Rev. Vaccines
, vol.14
, pp. 235-251
-
-
Van Lint, S.1
-
52
-
-
84885113945
-
A novel, disruptive vaccination technology: Self-adjuvanted RNActiveff vaccines
-
Kallen, K. J. et al. A novel, disruptive vaccination technology: self-adjuvanted RNActiveff vaccines. Hum. Vaccin Immunother. 9, 2263-2276 (2013).
-
(2013)
Hum. Vaccin Immunother.
, vol.9
, pp. 2263-2276
-
-
Kallen, K.J.1
-
53
-
-
85007273695
-
RNActiveff technology: Generation and testing of stable and immunogenic mRNA vaccines
-
Rauch, S., Lutz, J., Kowalczyk, A., Schlake, T. & Heidenreich, R. RNActiveff technology: generation and testing of stable and immunogenic mRNA vaccines. Methods Mol. Biol. 1499, 89-107 (2017).
-
(2017)
Methods Mol. Biol.
, vol.1499
, pp. 89-107
-
-
Rauch, S.1
Lutz, J.2
Kowalczyk, A.3
Schlake, T.4
Heidenreich, R.5
-
54
-
-
85010219814
-
Adjuvant effects of a sequence-engineered mRNA vaccine: Translational profiling demonstrates similar human and murine innate response
-
Edwards, D. K. et al. Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response. J. Transl Med. 15, 1 (2017).
-
(2017)
J. Transl Med.
, vol.15
, pp. 1
-
-
Edwards, D.K.1
-
55
-
-
84977497384
-
Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity
-
Kowalczyk, A. et al. Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity. Vaccine 34, 3882-3893 (2016).
-
(2016)
Vaccine
, vol.34
, pp. 3882-3893
-
-
Kowalczyk, A.1
-
56
-
-
84978063234
-
An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs
-
Schnee, M. et al. An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Negl. Trop. Dis. 10, e0004746 (2016).
-
(2016)
PLoS Negl. Trop. Dis.
, vol.10
, pp. e0004746
-
-
Schnee, M.1
-
57
-
-
85014587588
-
A new RNA-based adjuvant enhances virus-specific vaccine responses by locally triggering TLR-and RLH-dependent effects
-
Ziegler, A. et al. A new RNA-based adjuvant enhances virus-specific vaccine responses by locally triggering TLR-and RLH-dependent effects. J. Immunol. 198, 1595-1605 (2017).
-
(2017)
J. Immunol
, vol.198
, pp. 1595-1605
-
-
Ziegler, A.1
-
58
-
-
84921376995
-
mRNA-based dendritic cell vaccines
-
Benteyn, D., Heirman, C., Bonehill, A., Thielemans, K. & Breckpot, K. mRNA-based dendritic cell vaccines. Expert Rev. Vaccines 14, 161-176 (2015).
-
(2015)
Expert Rev. Vaccines
, vol.14
, pp. 161-176
-
-
Benteyn, D.1
Heirman, C.2
Bonehill, A.3
Thielemans, K.4
Breckpot, K.5
-
59
-
-
84975832642
-
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
-
Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396-401 (2016).
-
(2016)
Nature
, vol.534
, pp. 396-401
-
-
Kranz, L.M.1
-
60
-
-
0032145432
-
Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response
-
Wykes, M., Pombo, A., Jenkins, C. & MacPherson, G. G. Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response. J. Immunol. 161, 1313-1319 (1998).
-
(1998)
J. Immunol.
, vol.161
, pp. 1313-1319
-
-
Wykes, M.1
Pombo, A.2
Jenkins, C.3
MacPherson, G.G.4
-
61
-
-
84978909884
-
Uptake of synthetic naked RNA by skin-resident dendritic cells via macropinocytosis allows antigen expression and induction of T-cell responses in mice
-
Selmi, A. et al. Uptake of synthetic naked RNA by skin-resident dendritic cells via macropinocytosis allows antigen expression and induction of T-cell responses in mice. Cancer Immunol. Immunother. 65, 1075-1083 (2016).
-
(2016)
Cancer Immunol. Immunother.
, vol.65
, pp. 1075-1083
-
-
Selmi, A.1
-
62
-
-
79960145796
-
Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation
-
Diken, M. et al. Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther. 18, 702-708 (2011).
-
(2011)
Gene Ther.
, vol.18
, pp. 702-708
-
-
Diken, M.1
-
63
-
-
79960107932
-
Protein expression from exogenous mRNA: Uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway
-
Lorenz, C. et al. Protein expression from exogenous mRNA: uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway. RNA Biol. 8, 627-636 (2011).
-
(2011)
RNA Biol.
, vol.8
, pp. 627-636
-
-
Lorenz, C.1
-
64
-
-
0037383050
-
Electroporation: Theory and methods, perspectives for drug delivery, gene therapy and research
-
Gehl, J. Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol. Scand. 177, 437-447 (2003).
-
(2003)
Acta Physiol. Scand.
, vol.177
, pp. 437-447
-
-
Gehl, J.1
-
65
-
-
0033999511
-
Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA
-
Granstein, R. D., Ding, W. & Ozawa, H. Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA. J. Invest. Dermatol. 114, 632-636 (2000).
-
(2000)
J. Invest. Dermatol.
, vol.114
, pp. 632-636
-
-
Granstein, R.D.1
Ding, W.2
Ozawa, H.3
-
66
-
-
78549283854
-
Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity
-
Kreiter, S. et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res. 70, 9031-9040 (2010).
-
(2010)
Cancer Res.
, vol.70
, pp. 9031-9040
-
-
Kreiter, S.1
-
67
-
-
84960172757
-
Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours
-
Bialkowski, L. et al. Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours. Sci. Rep. 6, 22509 (2016).
-
(2016)
Sci. Rep.
, vol.6
, pp. 22509
-
-
Bialkowski, L.1
-
68
-
-
85024396858
-
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
-
Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222-226 (2017).
-
(2017)
Nature
, vol.547
, pp. 222-226
-
-
Sahin, U.1
-
69
-
-
0029875845
-
Gene gun delivery of mRNA in situ results in efficient transgene expression and genetic immunization
-
Qiu, P., Ziegelhoffer, P., Sun, J. & Yang, N. S. Gene gun delivery of mRNA in situ results in efficient transgene expression and genetic immunization. Gene Ther. 3, 262-268 (1996).
-
(1996)
Gene Ther.
, vol.3
, pp. 262-268
-
-
Qiu, P.1
Ziegelhoffer, P.2
Sun, J.3
Yang, N.S.4
-
70
-
-
27944481229
-
Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP. TRP2
-
Steitz, J., Britten, C. M., Wolfel, T. & Tuting, T. Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP. TRP2. Cancer Immunol. Immunother. 55, 246-253 (2006).
-
(2006)
Cancer Immunol. Immunother.
, vol.55
, pp. 246-253
-
-
Steitz, J.1
Britten, C.M.2
Wolfel, T.3
Tuting, T.4
-
71
-
-
29744449477
-
Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus
-
Aberle, J. H., Aberle, S. W., Kofler, R. M. & Mandl, C. W. Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus. J. Virol. 79, 15107-15113 (2005).
-
(2005)
J. Virol.
, vol.79
, pp. 15107-15113
-
-
Aberle, J.H.1
Aberle, S.W.2
Kofler, R.M.3
Mandl, C.W.4
-
72
-
-
1242296840
-
Mimicking live flavivirus immunization with a noninfectious RNA vaccine
-
Kofler, R. M. et al. Mimicking live flavivirus immunization with a noninfectious RNA vaccine. Proc. Natl Acad. Sci. USA 101, 1951-1956 (2004).
-
(2004)
Proc. Natl Acad. Sci. USA
, vol.101
, pp. 1951-1956
-
-
Kofler, R.M.1
-
73
-
-
0031787197
-
In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model
-
Mandl, C. W. et al. In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model. Nat. Med. 4, 1438-1440 (1998).
-
(1998)
Nat. Med.
, vol.4
, pp. 1438-1440
-
-
Mandl, C.W.1
-
74
-
-
84855383397
-
Intradermal electroporation of naked replicon RNA elicits strong immune responses
-
Johansson, D. X., Ljungberg, K., Kakoulidou, M. & Liljestrom, P. Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS ONE 7, e29732 (2012).
-
(2012)
PLoS ONE
, vol.7
, pp. e29732
-
-
Johansson, D.X.1
Ljungberg, K.2
Kakoulidou, M.3
Liljestrom, P.4
-
75
-
-
69249220233
-
Electroporation of RNA stimulates immunity to an encoded reporter gene in mice
-
Piggott, J. M., Sheahan, B. J., Soden, D. M., O'Sullivan, G. C. & Atkins, G. J. Electroporation of RNA stimulates immunity to an encoded reporter gene in mice. Mol. Med. Rep. 2, 753-756 (2009).
-
(2009)
Mol. Med. Rep.
, vol.2
, pp. 753-756
-
-
Piggott, J.M.1
Sheahan, B.J.2
Soden, D.M.3
O'Sullivan, G.C.4
Atkins, G.J.5
-
76
-
-
84921405665
-
Electroporation-enhanced delivery of nucleic acid vaccines
-
Broderick, K. E. & Humeau, L. M. Electroporation-enhanced delivery of nucleic acid vaccines. Expert Rev. Vaccines 14, 195-204 (2015).
-
(2015)
Expert Rev. Vaccines
, vol.14
, pp. 195-204
-
-
Broderick, K.E.1
Humeau, L.M.2
-
77
-
-
0033989908
-
In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies
-
Hoerr, I., Obst, R., Rammensee, H. G. & Jung, G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur. J. Immunol. 30, 1-7 (2000).
-
(2000)
Eur. J. Immunol.
, vol.30
, pp. 1-7
-
-
Hoerr, I.1
Obst, R.2
Rammensee, H.G.3
Jung, G.4
-
78
-
-
84870886906
-
Developing mRNA-vaccine technologies
-
Schlake, T., Thess, A., Fotin-Mleczek, M. & Kallen, K. J. Developing mRNA-vaccine technologies. RNA Biol. 9, 1319-1330 (2012).
-
(2012)
RNA Biol.
, vol.9
, pp. 1319-1330
-
-
Schlake, T.1
Thess, A.2
Fotin-Mleczek, M.3
Kallen, K.J.4
-
79
-
-
84964930086
-
mRNA vaccine delivery using lipid nanoparticles
-
Reichmuth, A. M., Oberli, M. A., Jeklenec, A., Langer, R. & Blankschtein, D. mRNA vaccine delivery using lipid nanoparticles. Ther. Deliv. 7, 319-334 (2016).
-
(2016)
Ther. Deliv.
, vol.7
, pp. 319-334
-
-
Reichmuth, A.M.1
Oberli, M.A.2
Jeklenec, A.3
Langer, R.4
Blankschtein, D.5
-
80
-
-
84921357504
-
Lipid-based mRNA vaccine delivery systems
-
Midoux, P. & Pichon, C. Lipid-based mRNA vaccine delivery systems. Expert Rev. Vaccines 14, 221-234 (2015).
-
(2015)
Expert Rev. Vaccines
, vol.14
, pp. 221-234
-
-
Midoux, P.1
Pichon, C.2
-
81
-
-
84886261520
-
Delivery materials for siRNA therapeutics
-
Kanasty, R., Dorkin, J. R., Vegas, A. & Anderson, D. Delivery materials for siRNA therapeutics. Nat. Mater. 12, 967-977 (2013).
-
(2013)
Nat. Mater.
, vol.12
, pp. 967-977
-
-
Kanasty, R.1
Dorkin, J.R.2
Vegas, A.3
Anderson, D.4
-
82
-
-
77954243341
-
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
-
Akinc, A. et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18, 1357-1364 (2010).
-
(2010)
Mol. Ther.
, vol.18
, pp. 1357-1364
-
-
Akinc, A.1
-
83
-
-
84982208611
-
Horizontal transfer of RNA and proteins between cells by extracellular microvesicles: 14 years later
-
Ratajczak, M. Z. & Ratajczak, J. Horizontal transfer of RNA and proteins between cells by extracellular microvesicles: 14 years later. Clin. Transl Med. 5, 7 (2016).
-
(2016)
Clin. Transl Med.
, vol.5
, pp. 7
-
-
Ratajczak, M.Z.1
Ratajczak, J.2
-
84
-
-
84992361752
-
Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination
-
Tam, H. H. et al. Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. Proc. Natl Acad. Sci. USA 113, E6639-E6648 (2016).
-
(2016)
Proc. Natl Acad. Sci. USA
, vol.113
, pp. E6639-E6648
-
-
Tam, H.H.1
-
85
-
-
85013067893
-
Modified mRNA Vaccines protect against Zika virus infection
-
Richner, J. M. et al. Modified mRNA Vaccines protect against Zika virus infection. Cell 168, 1114-1125. e10 (2017).
-
(2017)
Cell
, vol.168
, pp. 1114-1125e10
-
-
Richner, J.M.1
-
86
-
-
85010875070
-
Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem
-
Havenar-Daughton, C., Lee, J. H. & Crotty, S. Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem. Immunol. Rev. 275, 49-61 (2017).
-
(2017)
Immunol. Rev.
, vol.275
, pp. 49-61
-
-
Havenar-Daughton, C.1
Lee, J.H.2
Crotty, S.3
-
87
-
-
84921498605
-
Self-amplifying mRNA vaccines
-
Brito, L. A. et al. Self-amplifying mRNA vaccines. Adv. Genet. 89, 179-233 (2015).
-
(2015)
Adv. Genet.
, vol.89
, pp. 179-233
-
-
Brito, L.A.1
-
88
-
-
85020867312
-
An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model
-
Chahal, J. S. et al. An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model. Sci. Rep. 7, 252 (2017).
-
(2017)
Sci. Rep.
, vol.7
, pp. 252
-
-
Chahal, J.S.1
-
89
-
-
84978919993
-
Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose
-
Chahal, J. S. et al. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc. Natl Acad. Sci. USA 113, E4133-E4142 (2016).
-
(2016)
Proc. Natl Acad. Sci. USA
, vol.113
, pp. E4133-E4142
-
-
Chahal, J.S.1
-
90
-
-
84979695924
-
Recent innovations in mRNA vaccines
-
Ulmer, J. B. & Geall, A. J. Recent innovations in mRNA vaccines. Curr. Opin. Immunol. 41, 18-22 (2016).
-
(2016)
Curr. Opin. Immunol.
, vol.41
, pp. 18-22
-
-
Ulmer, J.B.1
Geall, A.J.2
-
91
-
-
85025815073
-
Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: An open-label, non-randomised, prospective, first-in-human phase 1 clinical trial
-
Alberer, M. et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet 390, 1511-1520 (2017).
-
(2017)
Lancet
, vol.390
, pp. 1511-1520
-
-
Alberer, M.1
-
92
-
-
0141521625
-
An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector
-
Perri, S. et al. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J. Virol. 77, 10394-10403 (2003).
-
(2003)
J. Virol.
, vol.77
, pp. 10394-10403
-
-
Perri, S.1
-
93
-
-
0035341935
-
Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus
-
Fleeton, M. N. et al. Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J. Infect. Dis. 183, 1395-1398 (2001).
-
(2001)
J. Infect. Dis.
, vol.183
, pp. 1395-1398
-
-
Fleeton, M.N.1
-
94
-
-
84984822445
-
Self-amplifying mRNA vaccines expressing multiple conserved influenza antigens confer protection against homologous and heterosubtypic viral challenge
-
Magini, D. et al. Self-amplifying mRNA vaccines expressing multiple conserved influenza antigens confer protection against homologous and heterosubtypic viral challenge. PLoS ONE 11, e0161193 (2016).
-
(2016)
PLoS ONE
, vol.11
, pp. e0161193
-
-
Magini, D.1
-
95
-
-
84883230210
-
Rapidly produced SAMff vaccine against H7N9 influenza is immunogenic in mice
-
Hekele, A. et al. Rapidly produced SAMff vaccine against H7N9 influenza is immunogenic in mice. Emerg. Microbes Infect. 2, e52 (2013).
-
(2013)
Emerg. Microbes Infect.
, vol.2
, pp. e52
-
-
Hekele, A.1
-
96
-
-
84953851839
-
Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin
-
Brazzoli, M. et al. Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin. J. Virol. 90, 332-344 (2015).
-
(2015)
J. Virol.
, vol.90
, pp. 332-344
-
-
Brazzoli, M.1
-
97
-
-
84924405861
-
Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion
-
Bogers, W. M. et al. Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. J. Infect. Dis. 211, 947-955 (2015).
-
(2015)
J. Infect. Dis.
, vol.211
, pp. 947-955
-
-
Bogers, W.M.1
-
98
-
-
84903789916
-
Self-replicating replicon-RNA delivery to dendritic cells by chitosan-nanoparticles for translation in vitro and in vivo
-
McCullough, K. C. et al. Self-replicating replicon-RNA delivery to dendritic cells by chitosan-nanoparticles for translation in vitro and in vivo. Mol. Ther. Nucleic Acids 3, e173 (2014).
-
(2014)
Mol. Ther. Nucleic Acids
, vol.3
, pp. e173
-
-
McCullough, K.C.1
-
99
-
-
84959335738
-
Polyethylenimine-based polyplex delivery of self-replicating RNA vaccines
-
Demoulins, T. et al. Polyethylenimine-based polyplex delivery of self-replicating RNA vaccines. Nanomedicine 12, 711-722 (2016).
-
(2016)
Nanomedicine
, vol.12
, pp. 711-722
-
-
Demoulins, T.1
-
100
-
-
85006983568
-
Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens
-
Maruggi, G. et al. Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens. Vaccine 35, 361-368 (2017).
-
(2017)
Vaccine
, vol.35
, pp. 361-368
-
-
Maruggi, G.1
-
101
-
-
84857045791
-
mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients
-
Van Gulck, E. et al. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. AIDS 26, F1-F12 (2012).
-
(2012)
AIDS
, vol.26
, pp. F1-F12
-
-
Van Gulck, E.1
-
102
-
-
73549125003
-
Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy
-
Routy, J. P. et al. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin. Immunol. 134, 140-147 (2010).
-
(2010)
Clin. Immunol.
, vol.134
, pp. 140-147
-
-
Routy, J.P.1
-
103
-
-
84857374529
-
A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption
-
Allard, S. D. et al. A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption. Clin. Immunol. 142, 252-268 (2012).
-
(2012)
Clin. Immunol.
, vol.142
, pp. 252-268
-
-
Allard, S.D.1
-
104
-
-
84959121365
-
Immunization of HIV-1-infected persons with autologous dendritic cells transfected with mRNA encoding HIV-1 Gag and Nef: Results of a randomized, placebo-controlled clinical trial
-
Gandhi, R. T. et al. Immunization of HIV-1-infected persons with autologous dendritic cells transfected with mRNA encoding HIV-1 Gag and Nef: results of a randomized, placebo-controlled clinical trial. J. Acquir. Immune Def. Syndr. 71, 246-253 (2016).
-
(2016)
J. Acquir. Immune Def. Syndr.
, vol.71
, pp. 246-253
-
-
Gandhi, R.T.1
-
105
-
-
84954509568
-
Dendritic cell immunotherapy for HIV-1 infection using autologous HIV-1 RNA: A randomized, double-blind, placebo-controlled clinical trial
-
Jacobson, J. M. et al. Dendritic cell immunotherapy for HIV-1 infection using autologous HIV-1 RNA: a randomized, double-blind, placebo-controlled clinical trial. J. Acquir. Immune Def. Syndr. 72, 31-38 (2016).
-
(2016)
J. Acquir. Immune Def. Syndr.
, vol.72
, pp. 31-38
-
-
Jacobson, J.M.1
-
106
-
-
85040812374
-
Immunogenicity of AGS-004 dendritic cell therapy in patients treated during acute HIV infection
-
Gay, C. L. et al. Immunogenicity of AGS-004 dendritic cell therapy in patients treated during acute HIV infection. AIDS Res. Hum. Retroviruses http://dx. doi. org/10. 1089/aid. 2017. 0071 (2017).
-
(2017)
AIDS Res. Hum. Retroviruses
-
-
Gay, C.L.1
-
107
-
-
84920265123
-
Induction of cytomegalovirus-specific T cell responses in healthy volunteers and allogeneic stem cell recipients using vaccination with messenger RNA-transfected dendritic cells
-
Van Craenenbroeck, A. H. et al. Induction of cytomegalovirus-specific T cell responses in healthy volunteers and allogeneic stem cell recipients using vaccination with messenger RNA-transfected dendritic cells. Transplantation 99, 120-127 (2015).
-
(2015)
Transplantation
, vol.99
, pp. 120-127
-
-
Van Craenenbroeck, A.H.1
-
108
-
-
0027170483
-
Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA
-
Martinon, F. et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur. J. Immunol. 23, 1719-1722 (1993).
-
(1993)
Eur. J. Immunol.
, vol.23
, pp. 1719-1722
-
-
Martinon, F.1
-
109
-
-
84871926389
-
Type i IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines
-
Pollard, C. et al. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol. Ther. 21, 251-259 (2013).
-
(2013)
Mol. Ther.
, vol.21
, pp. 251-259
-
-
Pollard, C.1
-
110
-
-
84991660875
-
Induction of HIV-1 gag specific immune responses by cationic micelles mediated delivery of gag mRNA
-
Zhao, M., Li, M., Zhang, Z., Gong, T. & Sun, X. Induction of HIV-1 gag specific immune responses by cationic micelles mediated delivery of gag mRNA. Drug Deliv. 23, 2596-2607 (2016).
-
(2016)
Drug Deliv.
, vol.23
, pp. 2596-2607
-
-
Zhao, M.1
Li, M.2
Zhang, Z.3
Gong, T.4
Sun, X.5
-
111
-
-
84961595277
-
Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra-and paracellular pathways
-
Li, M. et al. Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra-and paracellular pathways. J. Control. Release 228, 9-19 (2016).
-
(2016)
J. Control. Release
, vol.228
, pp. 9-19
-
-
Li, M.1
-
112
-
-
85023598743
-
Vaccine mediated protection against Zika virus-induced congenital disease
-
Richner, J. M. et al. Vaccine mediated protection against Zika virus-induced congenital disease. Cell 170, 273-283. e12 (2017).
-
(2017)
Cell
, vol.170
, pp. 273-283e12
-
-
Richner, J.M.1
-
113
-
-
77955937857
-
AS03(A)-adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age
-
Roman, F., Vaman, T., Kafeja, F., Hanon, E. & Van Damme, P. AS03(A)-adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin. Infect. Dis. 51, 668-677 (2010).
-
(2010)
Clin. Infect. Dis.
, vol.51
, pp. 668-677
-
-
Roman, F.1
Vaman, T.2
Kafeja, F.3
Hanon, E.4
Van Damme, P.5
-
114
-
-
84880664283
-
Immunogenicity and reactogenicity of two diphtheria-tetanus-whole cell pertussis vaccines in Iranian pre-school children, a randomized controlled trial
-
Zarei, S. et al. Immunogenicity and reactogenicity of two diphtheria-tetanus-whole cell pertussis vaccines in Iranian pre-school children, a randomized controlled trial. Hum. Vaccin. Immunother. 9, 1316-1322 (2013).
-
(2013)
Hum. Vaccin. Immunother.
, vol.9
, pp. 1316-1322
-
-
Zarei, S.1
-
115
-
-
85013083718
-
mRNA: A versatile molecule for cancer vaccines
-
Diken, M., Kranz, L. M., Kreiter, S. & Sahin, U. mRNA: a versatile molecule for cancer vaccines. Curr. Issues Mol. Biol. 22, 113-128 (2017).
-
(2017)
Curr. Issues Mol. Biol.
, vol.22
, pp. 113-128
-
-
Diken, M.1
Kranz, L.M.2
Kreiter, S.3
Sahin, U.4
-
116
-
-
85010422723
-
mRNA cancer vaccines
-
Fiedler, K., Lazzaro, S., Lutz, J., Rauch, S. & Heidenreich, R. mRNA cancer vaccines. Recent Results Cancer Res. 209, 61-85 (2016).
-
(2016)
Recent Results Cancer Res.
, vol.209
, pp. 61-85
-
-
Fiedler, K.1
Lazzaro, S.2
Lutz, J.3
Rauch, S.4
Heidenreich, R.5
-
118
-
-
84948807547
-
RNA-Based Vaccines in Cancer Immunotherapy
-
McNamara, M. A., Nair, S. K. & Holl, E. K. RNA-Based Vaccines in Cancer Immunotherapy. J. Immunol. Res. 2015, 794528 (2015).
-
(2015)
J. Immunol. Res.
, vol.2015
, pp. 794528
-
-
McNamara, M.A.1
Nair, S.K.2
Holl, E.K.3
-
119
-
-
84975045794
-
From the RNA world to the clinic
-
Sullenger, B. A. & Nair, S. From the RNA world to the clinic. Science 352, 1417-1420 (2016).
-
(2016)
Science
, vol.352
, pp. 1417-1420
-
-
Sullenger, B.A.1
Nair, S.2
-
120
-
-
84934344058
-
Human tumor antigens and cancer immunotherapy
-
Vigneron, N. Human tumor antigens and cancer immunotherapy. Biomed. Res. Int. 2015, 948501 (2015).
-
(2015)
Biomed. Res. Int.
, vol.2015
, pp. 948501
-
-
Vigneron, N.1
-
121
-
-
84966769739
-
Targeting the heterogeneity of cancer with individualized neoepitope vaccines
-
Tureci, O. et al. Targeting the heterogeneity of cancer with individualized neoepitope vaccines. Clin. Cancer Res. 22, 1885-1896 (2016).
-
(2016)
Clin. Cancer Res.
, vol.22
, pp. 1885-1896
-
-
Tureci, O.1
-
122
-
-
84894559188
-
Tumour antigens recognized by T lymphocytes: At the core of cancer immunotherapy
-
Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P. & Boon, T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat. Rev. Cancer 14, 135-146 (2014).
-
(2014)
Nat. Rev. Cancer
, vol.14
, pp. 135-146
-
-
Coulie, P.G.1
Van Den Eynde, B.J.2
Van Der Bruggen, P.3
Boon, T.4
-
123
-
-
0028965192
-
Characterization of a messenger RNA polynucleotide vaccine vector
-
Conry, R. M. et al. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res. 55, 1397-1400 (1995).
-
(1995)
Cancer Res.
, vol.55
, pp. 1397-1400
-
-
Conry, R.M.1
-
124
-
-
0029839058
-
Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
-
Boczkowski, D., Nair, S. K., Snyder, D. & Gilboa, E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184, 465-472 (1996).
-
(1996)
J. Exp. Med.
, vol.184
, pp. 465-472
-
-
Boczkowski, D.1
Nair, S.K.2
Snyder, D.3
Gilboa, E.4
-
125
-
-
79957868214
-
The combination of 4-1BBL and CD40L strongly enhances the capacity of dendritic cells to stimulate HIV-specific T cell responses
-
De Keersmaecker, B. et al. The combination of 4-1BBL and CD40L strongly enhances the capacity of dendritic cells to stimulate HIV-specific T cell responses. J. Leukoc. Biol. 89, 989-999 (2011).
-
(2011)
J. Leukoc. Biol.
, vol.89
, pp. 989-999
-
-
De Keersmaecker, B.1
-
126
-
-
17044427679
-
Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand
-
Dannull, J. et al. Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. Blood 105, 3206-3213 (2005).
-
(2005)
Blood
, vol.105
, pp. 3206-3213
-
-
Dannull, J.1
-
127
-
-
34147107441
-
CD83 expression on dendritic cells and T cells: Correlation with effective immune responses
-
Aerts-Toegaert, C. et al. CD83 expression on dendritic cells and T cells: correlation with effective immune responses. Eur. J. Immunol. 37, 686-695 (2007).
-
(2007)
Eur. J. Immunol.
, vol.37
, pp. 686-695
-
-
Aerts-Toegaert, C.1
-
128
-
-
23944454886
-
Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes
-
Grunebach, F. et al. Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes. Cancer Gene Ther. 12, 749-756 (2005).
-
(2005)
Cancer Gene Ther.
, vol.12
, pp. 749-756
-
-
Grunebach, F.1
-
129
-
-
45249113920
-
Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells
-
Bontkes, H. J., Kramer, D., Ruizendaal, J. J., Meijer, C. J. & Hooijberg, E. Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells. Clin. Immunol. 127, 375-384 (2008).
-
(2008)
Clin. Immunol.
, vol.127
, pp. 375-384
-
-
Bontkes, H.J.1
Kramer, D.2
Ruizendaal, J.J.3
Meijer, C.J.4
Hooijberg, E.5
-
130
-
-
33846912739
-
Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells
-
Bontkes, H. J. et al. Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells. Gene Ther. 14, 366-375 (2007).
-
(2007)
Gene Ther.
, vol.14
, pp. 366-375
-
-
Bontkes, H.J.1
-
131
-
-
38649110793
-
Introduction of functional chimeric E/L-selectin by RNA electroporation to target dendritic cells from blood to lymph nodes
-
Dorrie, J. et al. Introduction of functional chimeric E/L-selectin by RNA electroporation to target dendritic cells from blood to lymph nodes. Cancer Immunol. Immunother. 57, 467-477 (2008).
-
(2008)
Cancer Immunol. Immunother.
, vol.57
, pp. 467-477
-
-
Dorrie, J.1
-
132
-
-
44349173032
-
Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA
-
Bonehill, A. et al. Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol. Ther. 16, 1170-1180 (2008).
-
(2008)
Mol. Ther.
, vol.16
, pp. 1170-1180
-
-
Bonehill, A.1
-
133
-
-
84859417996
-
Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy
-
Van Lint, S. et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res. 72, 1661-1671 (2012).
-
(2012)
Cancer Res.
, vol.72
, pp. 1661-1671
-
-
Van Lint, S.1
-
134
-
-
84906939134
-
Optimized dendritic cell-based immunotherapy for melanoma: The TriMix-formula
-
Van Lint, S. et al. Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula. Cancer Immunol. Immunother. 63, 959-967 (2014).
-
(2014)
Cancer Immunol. Immunother.
, vol.63
, pp. 959-967
-
-
Van Lint, S.1
-
135
-
-
84881420246
-
Modulation of regulatory T cell function by monocyte-derived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4 and CD70
-
Pen, J. J. et al. Modulation of regulatory T cell function by monocyte-derived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4, and CD70. J. Immunol. 191, 1976-1983 (2013).
-
(2013)
J. Immunol.
, vol.191
, pp. 1976-1983
-
-
Pen, J.J.1
-
136
-
-
79957904174
-
Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma
-
Wilgenhof, S. et al. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J. Immunother. 34, 448-456 (2011).
-
(2011)
J. Immunother.
, vol.34
, pp. 448-456
-
-
Wilgenhof, S.1
-
137
-
-
84884721824
-
A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients
-
Wilgenhof, S. et al. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann. Oncol. 24, 2686-2693 (2013).
-
(2013)
Ann. Oncol.
, vol.24
, pp. 2686-2693
-
-
Wilgenhof, S.1
-
138
-
-
84925045090
-
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients
-
Mitchell, D. A. et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 519, 366-369 (2015).
-
(2015)
Nature
, vol.519
, pp. 366-369
-
-
Mitchell, D.A.1
-
139
-
-
85018819423
-
Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination
-
Batich, K. A. et al. Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination. Clin. Cancer Res. 23, 1898-1909 (2017).
-
(2017)
Clin. Cancer Res.
, vol.23
, pp. 1898-1909
-
-
Batich, K.A.1
-
140
-
-
84963629041
-
Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma
-
Wilgenhof, S. et al. Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma. J. Clin. Oncol. 34, 1330-1338 (2016).
-
(2016)
J. Clin. Oncol.
, vol.34
, pp. 1330-1338
-
-
Wilgenhof, S.1
-
141
-
-
0033231048
-
RNA melanoma vaccine: Induction of antitumor immunity by human glycoprotein 100 mRNA immunization
-
Zhou, W. Z. et al. RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization. Hum. Gene Ther. 10, 2719-2724 (1999).
-
(1999)
Hum. Gene Ther.
, vol.10
, pp. 2719-2724
-
-
Zhou, W.Z.1
-
142
-
-
84990216525
-
FLT3 ligand as a molecular adjuvant for naked RNA vaccines
-
Kreiter, S. et al. FLT3 ligand as a molecular adjuvant for naked RNA vaccines. Methods Mol. Biol. 1428, 163-175 (2016).
-
(2016)
Methods Mol. Biol.
, vol.1428
, pp. 163-175
-
-
Kreiter, S.1
-
143
-
-
80053347071
-
FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines
-
Kreiter, S. et al. FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines. Cancer Res. 71, 6132-6142 (2011).
-
(2011)
Cancer Res.
, vol.71
, pp. 6132-6142
-
-
Kreiter, S.1
-
144
-
-
84940486922
-
Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients
-
Bol, K. F. et al. Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients. Oncoimmunology 4, e1019197 (2015).
-
(2015)
Oncoimmunology
, vol.4
, pp. e1019197
-
-
Bol, K.F.1
-
145
-
-
84902097227
-
Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity
-
Phua, K. K., Staats, H. F., Leong, K. W. & Nair, S. K. Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity. Sci. Rep. 4, 5128 (2014).
-
(2014)
Sci. Rep.
, vol.4
, pp. 5128
-
-
Phua, K.K.1
Staats, H.F.2
Leong, K.W.3
Nair, S.K.4
-
146
-
-
33750248345
-
Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA
-
Scheel, B. et al. Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur. J. Immunol. 36, 2807-2816 (2006).
-
(2006)
Eur. J. Immunol.
, vol.36
, pp. 2807-2816
-
-
Scheel, B.1
-
147
-
-
84919889199
-
Intratumoral administration of mRNA encoding a fusokine consisting of IFN- and the ectodomain of the TGF- receptor II potentiates antitumor immunity
-
Van der Jeught, K. et al. Intratumoral administration of mRNA encoding a fusokine consisting of IFN- and the ectodomain of the TGF- receptor II potentiates antitumor immunity. Oncotarget 5, 10100-10113 (2014).
-
(2014)
Oncotarget
, vol.5
, pp. 10100-10113
-
-
Van Der Jeught, K.1
-
148
-
-
84962019868
-
Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells
-
Van Lint, S. et al. Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells. Cancer Immunol. Res. 4, 146-156 (2016).
-
(2016)
Cancer Immunol. Res.
, vol.4
, pp. 146-156
-
-
Van Lint, S.1
-
149
-
-
84946563295
-
Functional specialization of skin dendritic cell subsets in regulating T Cell responses
-
Clausen, B. E. & Stoitzner, P. Functional specialization of skin dendritic cell subsets in regulating T Cell responses. Front. Immunol. 6, 534 (2015).
-
(2015)
Front. Immunol.
, vol.6
, pp. 534
-
-
Clausen, B.E.1
Stoitzner, P.2
-
150
-
-
67651152679
-
Direct injection of protamine-protected mRNA: Results of a phase 1/2 vaccination trial in metastatic melanoma patients
-
Weide, B. et al. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J. Immunother. 32, 498-507 (2009).
-
(2009)
J. Immunother.
, vol.32
, pp. 498-507
-
-
Weide, B.1
-
151
-
-
84997666967
-
Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: A first-in-man phase I/IIa study
-
Kubler, H. et al. Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. J. Immunother. Cancer 3, 26 (2015).
-
(2015)
J. Immunother. Cancer
, vol.3
, pp. 26
-
-
Kubler, H.1
-
152
-
-
33644591595
-
Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen
-
Hess, P. R., Boczkowski, D., Nair, S. K., Snyder, D. & Gilboa, E. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. Cancer Immunol. Immunother. 55, 672-683 (2006).
-
(2006)
Cancer Immunol. Immunother.
, vol.55
, pp. 672-683
-
-
Hess, P.R.1
Boczkowski, D.2
Nair, S.K.3
Snyder, D.4
Gilboa, E.5
-
153
-
-
85014758993
-
Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy
-
Oberli, M. A. et al. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett. 17, 1326-1335 (2017).
-
(2017)
Nano Lett.
, vol.17
, pp. 1326-1335
-
-
Oberli, M.A.1
-
154
-
-
84862891254
-
Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect
-
Fotin-Mleczek, M. et al. Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. J. Gene Med. 14, 428-439 (2012).
-
(2012)
J. Gene Med.
, vol.14
, pp. 428-439
-
-
Fotin-Mleczek, M.1
-
155
-
-
84906841012
-
mRNA-based vaccines synergize with radiation therapy to eradicate established tumors
-
Fotin-Mleczek, M. et al. mRNA-based vaccines synergize with radiation therapy to eradicate established tumors. Radiat. Oncol. 9, 180 (2014).
-
(2014)
Radiat. Oncol.
, vol.9
, pp. 180
-
-
Fotin-Mleczek, M.1
-
156
-
-
3442896311
-
Messenger RNA-based vaccines
-
Pascolo, S. Messenger RNA-based vaccines. Expert Opin. Biol. Ther. 4, 1285-1294 (2004).
-
(2004)
Expert Opin. Biol. Ther.
, vol.4
, pp. 1285-1294
-
-
Pascolo, S.1
-
157
-
-
84882259948
-
RNA: The new revolution in nucleic acid vaccines
-
Geall, A. J., Mandl, C. W. & Ulmer, J. B. RNA: the new revolution in nucleic acid vaccines. Semin. Immunol. 25, 152-159 (2013).
-
(2013)
Semin. Immunol.
, vol.25
, pp. 152-159
-
-
Geall, A.J.1
Mandl, C.W.2
Ulmer, J.B.3
-
158
-
-
84878623156
-
HPLC purification of in vitro transcribed long RNA
-
Weissman, D., Pardi, N., Muramatsu, H. & Kariko, K. HPLC purification of in vitro transcribed long RNA. Methods Mol. Biol. 969, 43-54 (2013).
-
(2013)
Methods Mol. Biol.
, vol.969
, pp. 43-54
-
-
Weissman, D.1
Pardi, N.2
Muramatsu, H.3
Kariko, K.4
-
159
-
-
84953439628
-
Critical considerations for developing nucleic acid macromolecule based drug products
-
Muralidhara, B. K. et al. Critical considerations for developing nucleic acid macromolecule based drug products. Drug Discov. Today 21, 430-444 (2016).
-
(2016)
Drug Discov. Today
, vol.21
, pp. 430-444
-
-
Muralidhara, B.K.1
-
160
-
-
36448956746
-
Long-term storage of DNA-free RNA for use in vaccine studies
-
Jones, K. L., Drane, D. & Gowans, E. J. Long-term storage of DNA-free RNA for use in vaccine studies. Biotechniques 43, 675-681 (2007).
-
(2007)
Biotechniques
, vol.43
, pp. 675-681
-
-
Jones, K.L.1
Drane, D.2
Gowans, E.J.3
-
161
-
-
33746651192
-
Characterization of the ribonuclease activity on the skin surface
-
Probst, J. et al. Characterization of the ribonuclease activity on the skin surface. Genet. Vaccines Ther. 4, 4 (2006).
-
(2006)
Genet. Vaccines Ther.
, vol.4
, pp. 4
-
-
Probst, J.1
-
162
-
-
52449105777
-
-
U. S. Food & Drug Administration. U. S. Food & Drug Administration
-
U. S. Food & Drug Administration. Guidance for Industry: Considerations for plasmid DNA vaccines for infectious disease indications. U. S. Food & Drug Administration https://www. fda. gov/downloads/ BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/ Guidances/Vaccines/ucm091968. pdf (2007).
-
(2007)
Guidance for Industry: Considerations for Plasmid DNA Vaccines for Infectious Disease Indications
-
-
-
163
-
-
0003716537
-
-
U. S. Food & Drug Administration. U. S. Food & Drug Administration
-
U. S. Food & Drug Administration. Guidance for Industry: Guidance for human somatic cell therapy and gene therapy. U. S. Food & Drug Administration https://www. fda. gov/downloads/ BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/ Guidances/CellularandGeneTherapy/ucm081670. pdf (1998).
-
(1998)
Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy
-
-
-
164
-
-
84928169076
-
-
European Medicines Agency. European Commission
-
European Medicines Agency. Commission Directive 2009/120/EC. European Commission https://ec. europa. eu/health//sites/health/files/files/eudralex/ vol-1/dir-2009-120/dir-2009-120-en. pdf (2009).
-
(2009)
Commission Directive 2009/120/EC
-
-
-
165
-
-
85007163158
-
The European regulatory environment of RNA-based vaccines
-
Hinz, T. et al. The European regulatory environment of RNA-based vaccines. Methods Mol. Biol. 1499, 203-222 (2017).
-
(2017)
Methods Mol. Biol.
, vol.1499
, pp. 203-222
-
-
Hinz, T.1
-
166
-
-
85019702720
-
Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: Implications for vaccine design
-
Pepini, T. et al. Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design. J. Immunol. 198, 4012-4024 (2017).
-
(2017)
J. Immunol.
, vol.198
, pp. 4012-4024
-
-
Pepini, T.1
-
167
-
-
17644402442
-
Type i interferons (/) in immunity and autoimmunity
-
Theofilopoulos, A. N., Baccala, R., Beutler, B. & Kono, D. H. Type I interferons (/) in immunity and autoimmunity. Annu. Rev. Immunol. 23, 307-336 (2005).
-
(2005)
Annu. Rev. Immunol.
, vol.23
, pp. 307-336
-
-
Theofilopoulos, A.N.1
Baccala, R.2
Beutler, B.3
Kono, D.H.4
-
168
-
-
22344438901
-
Plasmacytoid predendritic cells initiate psoriasis through interferon- production
-
Nestle, F. O. et al. Plasmacytoid predendritic cells initiate psoriasis through interferon- production. J. Exp. Med. 202, 135-143 (2005).
-
(2005)
J. Exp. Med.
, vol.202
, pp. 135-143
-
-
Nestle, F.O.1
-
169
-
-
34948826463
-
Extracellular RNA mediates endothelial-cell permeability via vascular endothelial growth factor
-
Fischer, S. et al. Extracellular RNA mediates endothelial-cell permeability via vascular endothelial growth factor. Blood 110, 2457-2465 (2007).
-
(2007)
Blood
, vol.110
, pp. 2457-2465
-
-
Fischer, S.1
-
170
-
-
34447322451
-
Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation
-
Kannemeier, C. et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc. Natl Acad. Sci. USA 104, 6388-6393 (2007).
-
(2007)
Proc. Natl Acad. Sci. USA
, vol.104
, pp. 6388-6393
-
-
Kannemeier, C.1
-
171
-
-
33645871300
-
Human clinical trials of plasmid DNA vaccines
-
Liu, M. A. & Ulmer, J. B. Human clinical trials of plasmid DNA vaccines. Adv. Genet. 55, 25-40 (2005).
-
(2005)
Adv. Genet.
, vol.55
, pp. 25-40
-
-
Liu, M.A.1
Ulmer, J.B.2
-
172
-
-
85014766654
-
The 'anti-hype' vaccine
-
DeFrancesco, L. The 'anti-hype' vaccine. Nat. Biotechnol. 35, 193-197 (2017).
-
(2017)
Nat. Biotechnol.
, vol.35
, pp. 193-197
-
-
DeFrancesco, L.1
-
173
-
-
85011373272
-
On message
-
Servick, K. On message. Science 355, 446-450 (2017).
-
(2017)
Science
, vol.355
, pp. 446-450
-
-
Servick, K.1
-
174
-
-
85044636410
-
From science to patients - Ideas become treatments at CureVac
-
CureVac AG. From science to patients - ideas become treatments at CureVac. CureVac http://www. curevac. com/research-development (2017).
-
(2017)
CureVac
-
-
CureVac, A.G.1
-
175
-
-
85044623933
-
Aldevron expands North Dakota biomanufacturing facility
-
Aldevron. Aldevron expands North Dakota biomanufacturing facility. Aldevron http://www. aldevron. com/about-us/news/aldevron-expands-north-dakota-biomanufacturing-facility (2016).
-
(2016)
Aldevron
-
-
Aldevron1
-
176
-
-
84928811341
-
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
-
Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520, 692-696 (2015).
-
(2015)
Nature
, vol.520
, pp. 692-696
-
-
Kreiter, S.1
-
177
-
-
85024377220
-
An immunogenic personal neoantigen vaccine for patients with melanoma
-
Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217-221 (2017).
-
(2017)
Nature
, vol.547
, pp. 217-221
-
-
Ott, P.A.1
-
178
-
-
0016274718
-
Effect of thymus cell injections on germinal center formation in lymphoid tissues of nude (thymusless) mice
-
Jacobson, E. B., Caporale, L. H. & Thorbecke, G. J. Effect of thymus cell injections on germinal center formation in lymphoid tissues of nude (thymusless) mice. Cell. Immunol. 13, 416-430 (1974).
-
(1974)
Cell. Immunol.
, vol.13
, pp. 416-430
-
-
Jacobson, E.B.1
Caporale, L.H.2
Thorbecke, G.J.3
-
179
-
-
0028283841
-
Expression of the G-protein-coupled receptor BLR1 defines mature, recirculating B cells and a subset of T-helper memory cells
-
Forster, R., Emrich, T., Kremmer, E. & Lipp, M. Expression of the G-protein-coupled receptor BLR1 defines mature, recirculating B cells and a subset of T-helper memory cells. Blood 84, 830-840 (1994).
-
(1994)
Blood
, vol.84
, pp. 830-840
-
-
Forster, R.1
Emrich, T.2
Kremmer, E.3
Lipp, M.4
-
180
-
-
0030582773
-
A putative chemokine receptor BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen
-
Forster, R. et al. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 87, 1037-1047 (1996).
-
(1996)
Cell
, vol.87
, pp. 1037-1047
-
-
Forster, R.1
-
181
-
-
0034606359
-
Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production
-
Breitfeld, D. et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J. Exp. Med. 192, 1545-1552 (2000).
-
(2000)
J. Exp. Med.
, vol.192
, pp. 1545-1552
-
-
Breitfeld, D.1
-
182
-
-
0034606348
-
CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function
-
Schaerli, P. et al. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J. Exp. Med. 192, 1553-1562 (2000).
-
(2000)
J. Exp. Med.
, vol.192
, pp. 1553-1562
-
-
Schaerli, P.1
-
183
-
-
69249109601
-
Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation
-
Johnston, R. J. et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science 325, 1006-1010 (2009).
-
(2009)
Science
, vol.325
, pp. 1006-1010
-
-
Johnston, R.J.1
-
184
-
-
69249101229
-
Bcl6 mediates the development of T follicular helper cells
-
Nurieva, R. I. et al. Bcl6 mediates the development of T follicular helper cells. Science 325, 1001-1005 (2009).
-
(2009)
Science
, vol.325
, pp. 1001-1005
-
-
Nurieva, R.I.1
-
185
-
-
70049101558
-
The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment
-
Yu, D. et al. The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment. Immunity 31, 457-468 (2009).
-
(2009)
Immunity
, vol.31
, pp. 457-468
-
-
Yu, D.1
-
186
-
-
84923770324
-
A brief history of T cell help to B cells
-
Crotty, S. A brief history of T cell help to B cells. Nat. Rev. Immunol. 15, 185-189 (2015).
-
(2015)
Nat. Rev. Immunol.
, vol.15
, pp. 185-189
-
-
Crotty, S.1
-
187
-
-
84883796903
-
Antibodies in HIV-1 vaccine development and therapy
-
Klein, F. et al. Antibodies in HIV-1 vaccine development and therapy. Science 341, 1199-1204 (2013).
-
(2013)
Science
, vol.341
, pp. 1199-1204
-
-
Klein, F.1
-
188
-
-
85013630591
-
Biopharmaceuticals: Reference products and biosimilars to treat inflammatory diseases
-
Gils, A., Bertolotto, A., Mulleman, D., Bejan-Angoulvant, T. & Declerck, P. J. Biopharmaceuticals: reference products and biosimilars to treat inflammatory diseases. Ther. Drug Monit. 39, 308-315 (2017).
-
(2017)
Ther. Drug Monit.
, vol.39
, pp. 308-315
-
-
Gils, A.1
Bertolotto, A.2
Mulleman, D.3
Bejan-Angoulvant, T.4
Declerck, P.J.5
-
189
-
-
85014635920
-
Therapeutic antibodies for infectious diseases
-
Sparrow, E., Friede, M., Sheikh, M. & Torvaldsen, S. Therapeutic antibodies for infectious diseases. Bull. World Health Organ. 95, 235-237 (2017).
-
(2017)
Bull. World Health Organ.
, vol.95
, pp. 235-237
-
-
Sparrow, E.1
Friede, M.2
Sheikh, M.3
Torvaldsen, S.4
-
190
-
-
84958741132
-
The use of combinations of monoclonal antibodies in clinical oncology
-
Henricks, L. M., Schellens, J. H., Huitema, A. D. & Beijnen, J. H. The use of combinations of monoclonal antibodies in clinical oncology. Cancer Treat. Rev. 41, 859-867 (2015).
-
(2015)
Cancer Treat. Rev.
, vol.41
, pp. 859-867
-
-
Henricks, L.M.1
Schellens, J.H.2
Huitema, A.D.3
Beijnen, J.H.4
-
191
-
-
77952744612
-
Treatment of osteoporosis with denosumab
-
Lewiecki, E. M. Treatment of osteoporosis with denosumab. Maturitas 66, 182-186 (2010).
-
(2010)
Maturitas
, vol.66
, pp. 182-186
-
-
Lewiecki, E.M.1
-
192
-
-
85047288830
-
PCSK9 inhibitors: Monoclonal antibodies for the treatment of hypercholesterolemia
-
Paton, D. M. PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia. Drugs Today 52, 183-192 (2016).
-
(2016)
Drugs Today
, vol.52
, pp. 183-192
-
-
Paton, D.M.1
-
193
-
-
85020211708
-
State of play and clinical prospects of antibody gene transfer
-
Hollevoet, K. & Declerck, P. J. State of play and clinical prospects of antibody gene transfer. J. Transl Med. 15, 131 (2017).
-
(2017)
J. Transl Med.
, vol.15
, pp. 131
-
-
Hollevoet, K.1
Declerck, P.J.2
-
194
-
-
85015257690
-
Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies
-
Fuchs, S. P. & Desrosiers, R. C. Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. Mol. Ther. Methods Clin. Dev. 3, 16068 (2016).
-
(2016)
Mol. Ther. Methods Clin. Dev.
, vol.3
, pp. 16068
-
-
Fuchs, S.P.1
Desrosiers, R.C.2
-
195
-
-
70449637946
-
Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immuno-therapy
-
Boczkowski, D., Lee, J., Pruitt, S. & Nair, S. Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immuno-therapy. Cancer Gene Ther. 16, 900-911 (2009).
-
(2009)
Cancer Gene Ther.
, vol.16
, pp. 900-911
-
-
Boczkowski, D.1
Lee, J.2
Pruitt, S.3
Nair, S.4
-
196
-
-
82255181369
-
Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells
-
Pruitt, S. K. et al. Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. Eur. J. Immunol. 41, 3553-3563 (2011).
-
(2011)
Eur. J. Immunol.
, vol.41
, pp. 3553-3563
-
-
Pruitt, S.K.1
-
197
-
-
85014176711
-
Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge
-
Pardi, N. et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat. Commun. 8, 14630 (2017).
-
(2017)
Nat. Commun.
, vol.8
, pp. 14630
-
-
Pardi, N.1
-
198
-
-
85023757545
-
Elimination of large tumors in mice by mRNA-encoded bispecific antibodies
-
Stadler, C. R. et al. Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. Nat. Med. 23, 815-817 (2017).
-
(2017)
Nat. Med.
, vol.23
, pp. 815-817
-
-
Stadler, C.R.1
-
199
-
-
85030264484
-
mRNA mediates passive vaccination against infectious agents, toxins, and tumors
-
Thran, M. et al. mRNA mediates passive vaccination against infectious agents, toxins, and tumors. EMBO Mol. Med. 9, 1434-1447 (2017).
-
(2017)
EMBO Mol. Med.
, vol.9
, pp. 1434-1447
-
-
Thran, M.1
-
200
-
-
84908060936
-
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActiveff) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer
-
Sebastian, M. et al. Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActiveff) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer 14, 748 (2014).
-
(2014)
BMC Cancer
, vol.14
, pp. 748
-
-
Sebastian, M.1
-
201
-
-
84873406290
-
Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy
-
Wang, Y. et al. Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol. Ther. 21, 358-367 (2013).
-
(2013)
Mol. Ther.
, vol.21
, pp. 358-367
-
-
Wang, Y.1
-
202
-
-
79960725328
-
Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA
-
Perche, F. et al. Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA. Nanomedicine 7, 445-453 (2011).
-
(2011)
Nanomedicine
, vol.7
, pp. 445-453
-
-
Perche, F.1
-
203
-
-
34547919965
-
mRNA-based cancer vaccine: Prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes
-
Mockey, M. et al. mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes. Cancer Gene Ther. 14, 802-814 (2007).
-
(2007)
Cancer Gene Ther.
, vol.14
, pp. 802-814
-
-
Mockey, M.1
-
204
-
-
84957561169
-
Systemic delivery of messenger RNA for the treatment of pancreatic cancer using polyplex nanomicelles with a cholesterol moiety
-
Uchida, S. et al. Systemic delivery of messenger RNA for the treatment of pancreatic cancer using polyplex nanomicelles with a cholesterol moiety. Biomaterials 82, 221-228 (2016).
-
(2016)
Biomaterials
, vol.82
, pp. 221-228
-
-
Uchida, S.1
-
205
-
-
84941746198
-
CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes
-
Lazzaro, S. et al. CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes. Immunology 146, 312-326 (2015).
-
(2015)
Immunology
, vol.146
, pp. 312-326
-
-
Lazzaro, S.1
-
206
-
-
70849118552
-
Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase i dose-escalation clinical trial
-
Van Driessche, A. et al. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy 11, 653-668 (2009).
-
(2009)
Cytotherapy
, vol.11
, pp. 653-668
-
-
Van Driessche, A.1
-
207
-
-
77956384935
-
Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination
-
Van Tendeloo, V. F. et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc. Natl Acad. Sci. USA 107, 13824-13829 (2010).
-
(2010)
Proc. Natl Acad. Sci. USA
, vol.107
, pp. 13824-13829
-
-
Van Tendeloo, V.F.1
-
208
-
-
84939467081
-
Dendritic cell vaccination in malignant pleural mesothelioma: A phase I/II study [abstract]
-
Berneman, Z. N. et al. Dendritic cell vaccination in malignant pleural mesothelioma: a phase I/II study [abstract]. J. Clin. Oncol. 32 (Suppl.), 7583 (2014).
-
(2014)
J. Clin. Oncol.
, vol.32
, pp. 7583
-
-
Berneman, Z.N.1
-
209
-
-
84997817430
-
Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
-
Amin, A. et al. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): phase 2 study results. J. Immunother. Cancer 3, 14 (2015).
-
(2015)
J. Immunother. Cancer
, vol.3
, pp. 14
-
-
Amin, A.1
-
210
-
-
85017551412
-
Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia
-
Khoury, H. J. et al. Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia. Cancer 123, 3061-3072 (2017).
-
(2017)
Cancer
, vol.123
, pp. 3061-3072
-
-
Khoury, H.J.1
-
211
-
-
84870955822
-
Messenger RNA vaccination in NSCLC: Findings from a phase I/IIa clinical trial [abstract]
-
Sebastian, M. et al. Messenger RNA vaccination in NSCLC: findings from a phase I/IIa clinical trial [abstract]. J. Clin. Oncol. 29 (Suppl.), 2584 (2011).
-
(2011)
J. Clin. Oncol.
, vol.29
, pp. 2584
-
-
Sebastian, M.1
-
212
-
-
84921404852
-
mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer
-
Rausch, S., Schwentner, C., Stenzl, A. & Bedke, J. mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer. Hum. Vaccin Immunother. 10, 3146-3152 (2014).
-
(2014)
Hum. Vaccin Immunother.
, vol.10
, pp. 3146-3152
-
-
Rausch, S.1
Schwentner, C.2
Stenzl, A.3
Bedke, J.4
-
213
-
-
80052919974
-
Monoclonal antibody blockade of IL-2 receptor during lymphopenia selectively depletes regulatory T cells in mice and humans
-
Mitchell, D. A. et al. Monoclonal antibody blockade of IL-2 receptor during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood 118, 3003-3012 (2011).
-
(2011)
Blood
, vol.118
, pp. 3003-3012
-
-
Mitchell, D.A.1
-
214
-
-
84988874485
-
mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma
-
Borch, T. H. et al. mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma. Oncoimmunology 5, e1207842 (2016).
-
(2016)
Oncoimmunology
, vol.5
, pp. e1207842
-
-
Borch, T.H.1
-
215
-
-
85012914647
-
Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study
-
Kongsted, P. et al. Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: a randomized phase II study. Cytotherapy 19, 500-513 (2017).
-
(2017)
Cytotherapy
, vol.19
, pp. 500-513
-
-
Kongsted, P.1
-
216
-
-
84994111950
-
Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells
-
Kyte, J. A. et al. Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells. Oncoimmunology 5, e1232237 (2016).
-
(2016)
Oncoimmunology
, vol.5
, pp. e1232237
-
-
Kyte, J.A.1
-
217
-
-
84883458285
-
Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma
-
Vik-Mo, E. O. et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol. Immunother. 62, 1499-1509 (2013).
-
(2013)
Cancer Immunol. Immunother.
, vol.62
, pp. 1499-1509
-
-
Vik-Mo, E.O.1
-
218
-
-
78751504910
-
Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients
-
Lesterhuis, W. J. et al. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Anticancer Res. 30, 5091-5097 (2010).
-
(2010)
Anticancer Res.
, vol.30
, pp. 5091-5097
-
-
Lesterhuis, W.J.1
-
219
-
-
84866945151
-
Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients
-
Aarntzen, E. H. et al. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin. Cancer Res. 18, 5460-5470 (2012).
-
(2012)
Clin. Cancer Res.
, vol.18
, pp. 5460-5470
-
-
Aarntzen, E.H.1
-
220
-
-
84908667491
-
Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients
-
Bol, K. F. et al. Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients. Am. J. Ophthalmol. 158, 939-947 (2014).
-
(2014)
Am. J. Ophthalmol.
, vol.158
, pp. 939-947
-
-
Bol, K.F.1
-
221
-
-
84959544986
-
Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity
-
Bol, K. F. et al. Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity. Cancer Immunol. Immunother. 65, 327-339 (2016).
-
(2016)
Cancer Immunol. Immunother.
, vol.65
, pp. 327-339
-
-
Bol, K.F.1
-
222
-
-
44949195901
-
Results of the first phase I/II clinical vaccination trial with direct injection of mRNA
-
Weide, B. et al. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J. Immunother. 31, 180-188 (2008).
-
(2008)
J. Immunother.
, vol.31
, pp. 180-188
-
-
Weide, B.1
|